KURA insider filings
Kura Oncology, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-29. Screen KURA transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 11 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings by 1 insider — 200,000 shares, $2,351,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 12 legs across 8 filings by 6 insiders — 153,881 shares, $1,708,041 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
- Largest priced transaction: purchase of 100,000 shares @ $12.39 ($1,239,000) by WILSON TROY EDWARD, filed 2026-08-24.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| WILSON TROY EDWARD — President and CEO, Director | 2 | 2 legs · 200,000 sh · $2,351,000 | — | — |
| Bair Teresa Brophy — Chief Legal Officer | 2 | — | 2 legs · 39,929 sh · $486,299 | — |
| Leoni Mollie — Chief Medical Officer | 1 | — | 2 legs · 41,250 sh · $440,237 | — |
| Powl Brian T. — Chief Commercial Officer | 2 | — | 4 legs · 36,795 sh · $396,699 | — |
| Burrows Francis — Chief Scientific Officer | 1 | — | 1 leg · 20,726 sh · $224,514 | 2 |
| FORD KATHLEEN — Chief Operating Officer | 1 | — | 2 legs · 10,574 sh · $111,931 | — |
| DOYLE THOMAS JAMES — SVP, Finance & Accounting | 1 | — | 1 leg · 4,607 sh · $48,361 | — |
| Fulk Jennifer — Chief Financial Officer | 1 | — | — | 1 |
Recent insider filings — Kura Oncology, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-29 | 4 | Powl Brian T. — Chief Commercial Officer | Sale (S): 9,020 @ $10.50 · Sale (S): 8,000 @ $10.56 · Sale (S): 15,430 @ $10.75 | EDGAR |
| 2026-09-29 | 4 | DOYLE THOMAS JAMES — SVP, Finance & Accounting | Sale (S): 4,607 @ $10.50 | EDGAR |
| 2026-09-29 | 4 | Leoni Mollie — Chief Medical Officer | Sale (S): 12,448 @ $10.50 · Sale (S): 28,802 @ $10.75 | EDGAR |
| 2026-09-29 | 4 | FORD KATHLEEN — Chief Operating Officer | Sale (S): 6,906 @ $10.50 · Sale (S): 3,668 @ $10.75 | EDGAR |
| 2026-09-29 | 4 | Bair Teresa Brophy — Chief Legal Officer | Sale (S): 8,442 @ $10.50 | EDGAR |
| 2026-09-25 | 4 | Burrows Francis — Chief Scientific Officer | Option exercise (M): 30,000 @ $6.15 · Sale (S): 20,726 @ $10.83 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-09-10 | 4 | Fulk Jennifer — Chief Financial Officer | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2026-08-24 | 4 | WILSON TROY EDWARD — President and CEO, Director | Purchase (P): 100,000 @ $12.39 | EDGAR |
| 2026-08-24 | 4 | Powl Brian T. — Chief Commercial Officer | Sale (S): 4,345 @ $11.89 | EDGAR |
| 2026-08-21 | 4 | Bair Teresa Brophy — Chief Legal Officer | Sale (S): 31,487 @ $12.63 | EDGAR |
| 2026-08-17 | 4 | WILSON TROY EDWARD — President and CEO, Director | Purchase (P): 100,000 @ $11.12 | EDGAR |
| 2026-06-22 | 4 | Leoni Mollie — Chief Medical Officer | Sale (S): 84,929 @ $9.82 | EDGAR |
| 2026-06-04 | 4 | Parks Diane L. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | VASCONCELLES MICHAEL — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Collins Helen Louise — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Szela Mary T — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Malley Thomas — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Hasnain Faheem — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | SCHAFER CAROL — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Powl Brian T. — Chief Commercial Officer | Sale (S): 10,000 @ $11 | EDGAR |
| 2026-05-20 | 4 | FORD KATHLEEN — Chief Operating Officer | Sale (S): 2,257 @ $9.08 | EDGAR |
| 2026-05-20 | 4 | Powl Brian T. — Chief Commercial Officer | Sale (S): 339 @ $9.21 | EDGAR |
| 2026-05-20 | 4 | Bair Teresa Brophy — Chief Legal Officer | Sale (S): 2,256 @ $9.38 | EDGAR |
| 2026-03-25 | 4 | WILSON TROY EDWARD — President and CEO, Director | Option exercise (M): 6,103 @ $6.15 · Option exercise (M): 6,103 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Malley Thomas — Director | Option exercise (M): 10,000 @ $3.12 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Burrows Francis — Chief Scientific Officer | Sale (S): 1,311 @ $8.46 | EDGAR |
| 2026-01-27 | 4 | Powl Brian T. — Chief Commercial Officer | Sale (S): 4,842 @ $8.46 · Sale (S): 1,572 @ $8.46 | EDGAR |
| 2026-01-27 | 4 | FORD KATHLEEN — Chief Operating Officer | Sale (S): 1,813 @ $8.46 | EDGAR |
| 2026-01-27 | 4 | Leoni Mollie — Chief Medical Officer | Sale (S): 3,655 @ $8.46 · Sale (S): 2,233 @ $8.46 · Sale (S): 951 @ $8.46 · Sale (S): 1,341 @ $8.46 | EDGAR |
| 2026-01-27 | 4 | DOYLE THOMAS JAMES — SVP, Finance & Accounting | Sale (S): 2,226 @ $8.46 · Sale (S): 1,114 @ $8.46 · Sale (S): 695 @ $8.46 · Sale (S): 2,226 @ $8.46 · Sale (S): 881 @ $8.46 | EDGAR |
| 2026-01-27 | 4 | Bair Teresa Brophy — Chief Legal Officer | Sale (S): 4,096 @ $8.46 · Sale (S): 2,335 @ $8.46 · Sale (S): 4,777 @ $8.46 | EDGAR |
| 2026-01-06 | 4 | WILSON TROY EDWARD — President and CEO, Director | Grant/award (A): 1,120,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Leoni Mollie — Chief Medical Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | DOYLE THOMAS JAMES — SVP, Finance & Accounting | Grant/award (A): 21,250 @ $0 · Grant/award (A): 42,500 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | FORD KATHLEEN — Chief Operating Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Burrows Francis — Chief Scientific Officer | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Powl Brian T. — Chief Commercial Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Bair Teresa Brophy — Chief Legal Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Burrows Francis — Chief Scientific Officer | Option exercise (M): 35,000 @ $4.80 · Sale (S): 23,726 @ $9.78 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Hasnain Faheem — Director | Option exercise (M): 10,000 @ $3.12 · Sale (S): 10,000 @ $10.98 | EDGAR |
| 2025-11-14 | 4 | Bair Teresa Brophy — Chief Legal Officer | Grant/award (A): 48,900 @ $0 · Sale (S): 8,804 @ $11.18 | EDGAR |
| 2025-11-14 | 4 | WILSON TROY EDWARD — President and CEO, Director | Grant/award (A): 182,500 @ $0 | EDGAR |
| 2025-11-14 | 4 | Powl Brian T. — Chief Commercial Officer | Grant/award (A): 48,900 @ $0 · Sale (S): 8,887 @ $11.18 | EDGAR |
| 2025-11-14 | 4 | Leoni Mollie — Chief Medical Officer | Grant/award (A): 82,500 @ $0 · Sale (S): 15,485 @ $11.18 | EDGAR |
| 2025-11-14 | 4 | DOYLE THOMAS JAMES — SVP, Finance & Accounting | Grant/award (A): 24,967 @ $0 · Sale (S): 4,539 @ $11.18 | EDGAR |
| 2025-11-14 | 4 | FORD KATHLEEN — Chief Operating Officer | Grant/award (A): 48,900 @ $0 · Sale (S): 6,902 @ $11.18 | EDGAR |
| 2025-09-29 | 4 | FORD KATHLEEN — Chief Operating Officer | Grant/award (A): 48,900 @ $0 · Sale (S): 6,892 @ $8.94 | EDGAR |
| 2025-09-29 | 4 | Leoni Mollie — Chief Medical Officer | Grant/award (A): 82,500 @ $0 · Sale (S): 12,314 @ $8.94 | EDGAR |
| 2025-09-29 | 4 | WILSON TROY EDWARD — President and CEO, Director | Grant/award (A): 182,500 @ $0 · Sale (S): 36,615 @ $8.94 | EDGAR |
| 2025-09-29 | 4 | DOYLE THOMAS JAMES — SVP, Finance & Accounting | Grant/award (A): 24,966 @ $0 · Sale (S): 4,541 @ $8.94 | EDGAR |
Recent 8-K events — Kura Oncology, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-09 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-29 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-02 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KURA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →